Rubraca improves PFS in first-line maintenance treatment of ovarian cancer regardless of biomarker status in phase III ATHENA-MONO trial

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.

September 06, 2024

Vol.50 No.33

In Brief

Alex Morozov named chief medical officer at Pi Health

Alex Morozov was named the first chief medical officer of Pi Health, an oncology clinical trial and research technology company.

August 09, 2024

Vol.50 No.32

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

Language barriers hinder diverse recruitment to clinical trials

Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.

August 02, 2024

Vol.50 No.31

Clinical Roundup

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

IMUNON Inc., a clinical-stage company in late-stage development of its DNA-mediated immunotherapy, announced positive topline results from the phase II OVATION 2 study with IMNN-001 in patients with advanced ovarian cancer.

August 02, 2024

Vol.50 No.31

Regulatory News

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Rubraca improves PFS in first-line maintenance treatment of ovarian cancer regardless of biomarker status in phase III ATHENA-MONO trial

YOU MAY BE INTERESTED IN

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Alex Morozov named chief medical officer at Pi Health

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Rubraca improves PFS in first-line maintenance treatment of ovarian cancer regardless of biomarker status in phase III ATHENA-MONO trial

YOU MAY BE INTERESTED IN

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Alex Morozov named chief medical officer at Pi Health

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

IMNN-001 immunotherapy improved PFS in newly-diagnosed advanced ovarian cancer in phase II study

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Can you spare 10 minutes to complete a survey?

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC